Presented by Zia H Shah MD with the help of Gemini

Audio teaser: Daily Melatonin Protects the Aging Brain

Introduction: The Chronobiology of Aging and the Melatonin Deficit

The demographic shift towards a rapidly aging global population necessitates a paradigm shift in how modern medicine approaches geriatric health span and longevity. While chronological age is an inevitable progression, biological aging is characterized by specific, identifiable, and frequently modifiable pathophysiological declines. One of the most universally documented, yet clinically underappreciated, alterations in the aging human is the progressive senescence of the pineal gland and the subsequent collapse of endogenous melatonin production.

For decades, melatonin (N-acetyl-5-methoxytryptamine) has been narrowly classified by the general medical community as a simple chronobiotic—an over-the-counter sleep aid utilized primarily for jet lag or transient insomnia. However, an exhaustive review of cellular biology, neurology, and endocrinology reveals that melatonin is a highly conserved, pleiotropic molecule acting as a terminal antioxidant, an immunomodulator, a mitochondrial protectant, and a genomic regulator. The scientific literature consistently demonstrates that age-related depletion of melatonin contributes significantly not only to primary sleep disorders in the elderly but also to a cascade of non-circadian age-related pathologies, including neurodegenerative diseases, cardiovascular dysregulation, osteopenia, and ocular degeneration.

Drawing upon three decades of clinical practice in sleep medicine, personal clinical observation, and an exhaustive review of the literature, this report advances a formal clinical proposal: the regular, daily administration of exogenous melatonin for all seniors over the age of 60, taken at a fixed and regular bedtime. This universal supplementation strategy aims to restore the physiological circadian amplitude lost to age, counteract systemic oxidative stress, and provide broad-spectrum protection against the ravages of senescence.

The Pathophysiology of Pineal Senescence

The endogenous production of melatonin is inextricably linked to the structural integrity of the pineal gland. With advancing chronological age, the pineal gland undergoes profound morphological and degenerative changes that severely limit its functional capacity.

Structural and Molecular Deterioration

Chief among these degenerative changes is pineal calcification (PGC), characterized by the formation of concretions known as corpora arenacea. The incidence of pineal calcification increases directly with age, severely jeopardizing the gland’s synthetic capacity and serving as a reliable indicator of an intra-individual deficit in 6-sulfatoxymelatonin (aMT6s) excretion, the primary urinary metabolite of melatonin.

The pathogenesis of this calcification is not entirely passive. It is driven by osteoblast-like cells differentiating from mesenchymal stem cells (MSCs) within the pineal gland. Because the pineal gland possesses an extraordinarily high blood filtration rate—second only to the kidney—it is uniquely vulnerable to systemic chronic vascular inflammation and hemodynamic stress. Pro-inflammatory cytokines, transforming growth factor-beta (TGF-β), and tumor necrosis factor-alpha (TNF-α) mobilize MSC migration and adhesion in the gland. Furthermore, states of brain tissue hypoxia (induced by conditions such as sleep apnea or hypertension) upregulate Hypoxia-inducible factor (HIF)-1α, which further promotes MSC proliferation and subsequent osteoblastic differentiation in the hypoxic microenvironment.

In addition to physical calcification, gliosis, and cyst formation, the aging pineal gland experiences a marked reduction in the density of β-adrenergic receptors. Nocturnal melatonin synthesis is driven by sympathetic nervous system projections from the superior cervical ganglion releasing norepinephrine to stimulate these β1-adrenergic receptors. The loss of receptor density drastically impairs the signal transduction required for melatonin biosynthesis.

The realization that pineal calcification and melatonin depletion fulfill all standard criteria for an aging-related pathology implies that replenishing this hormone is a fundamental hormone replacement therapy designed to restore a critical biological timing and defense mechanism.

Pharmacokinetics and Safety in the Geriatric Population

To advocate for the universal administration of a biologically active compound across an entire demographic, the pharmacokinetic and safety profile must be rigorously established. Melatonin demonstrates a remarkably favorable profile, even amidst the metabolic changes inherent to aging.

CYP1A2 Metabolism and Bioavailability

Orally administered melatonin undergoes extensive first-pass metabolism in the liver, primarily catalyzed by the cytochrome P450 1A2 (CYP1A2) enzyme, with a minor contribution from CYP2C19. It is metabolized into 6-hydroxymelatonin, conjugated with sulfuric or glucuronic acid, and excreted in the urine as 6-sulfatoxymelatonin. Due to substantial interindividual variability in CYP1A2 activity, the oral bioavailability of melatonin ranges broadly from 1% to 37%.

It is vital to recognize that common dietary and pharmacological agents interact with CYP1A2, thereby altering melatonin clearance. Caffeine is a competitive substrate for CYP1A2; its evening ingestion significantly inhibits melatonin metabolism, thereby raising serum melatonin levels by over 40%. Similarly, oral contraceptives and certain targeted therapeutics (such as the tyrosine kinase inhibitor apatinib) exert significant inhibitory effects on CYP1A2, amplifying systemic melatonin exposure.

Geriatric Considerations and Safety Profile

In the elderly, the pharmacokinetic behavior of melatonin remains remarkably linear. Studies directly comparing low-dose (0.4 mg) and high-dose (4.0 mg) surge-sustained release formulations in older adults demonstrate that the apparent clearance, volume of distribution, and elimination half-life remain constant across the dose range. The elimination half-life for oral formulations generally ranges from 45 to 65 minutes, preventing dangerous bioaccumulation. Extensive clinical monitoring has demonstrated that even six weeks of high-dose melatonin therapy does not induce hepatotoxicity, renal impairment, or shifts in serum creatinine in the elderly.

Crucially, melatonin exhibits exceptionally low acute toxicity. In animal models, an LD50 cannot be established even at astronomical doses (up to 800 mg/kg), and no fatalities have been recorded. Systematic reviews confirm that in the geriatric population, melatonin does not trigger dangerous hypothermia, rebound insomnia, or the withdrawal syndromes universally seen with sedative-hypnotic drugs.

Efficacy and Safety in Geriatric Primary Sleep Disorders

Aging is universally associated with a deterioration in sleep architecture, primarily characterized by increased sleep onset latency, reduced total sleep time, and a severe reduction in deep, slow-wave sleep and Rapid Eye Movement (REM) sleep. The disruption of the circadian rhythm acts as a significant risk factor for chronic insomnia in the elderly.

Restoring Sleep Architecture

Meta-analyses of randomized controlled trials (RCTs) confirm the efficacy of melatonin in mitigating primary sleep disorders in older adults. Exogenous melatonin administration significantly reduces sleep onset latency. Objective measures demonstrate that subjects fall asleep approximately 7 to 10 minutes faster on average, with trials of longer duration and higher doses showing even greater effects. Furthermore, melatonin reliably increases total sleep time by an average of 8 to 12 minutes and significantly improves overall subjective sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI).

While a 10-minute reduction in sleep latency may seem numerically modest compared to potent sedative-hypnotics, it is crucial to recognize that melatonin operates as a chronobiotic, entraining the circadian pacemaker, rather than a central nervous system depressant. Prolonged-release (PR) melatonin formulations (typically 2 mg) have shown substantial and sustained efficacy in primary insomnia among patients aged 55 and older, yielding significant improvements in sleep quality, morning alertness, and behavioral integrity the following morning, without evidence of tolerance or rebound insomnia upon cessation.

The Imperative to Replace Benzodiazepines

The recommendation for universal melatonin adoption in the over-60 demographic is powerfully underscored by the current, highly detrimental reliance on benzodiazepines and Z-drugs (e.g., zolpidem). Currently, nearly 17% of individuals over the age of 85 are prescribed benzodiazepines, despite overwhelming evidence of questionable clinical benefit and severe iatrogenic harm. Benzodiazepines reduce sleep onset latency by merely 4.2 minutes and provide a modest increase in sleep duration that rapidly wanes due to tolerance.

The adverse effect profile of benzodiazepines in the elderly is catastrophic, including elevated risks of cognitive decline, delirium, dependency, and a drastically increased risk of falls and subsequent hip fractures. By contrast, melatonin is inherently safe, exhibiting no withdrawal effects, no dependence potential, and no negative impact on cognitive performance or activities of daily living. Transitioning the geriatric population from benzodiazepines to melatonin—administered at a fixed evening hour—represents a profound opportunity to reduce morbidity and polypharmacy-related mortality.

The Iatrogenic Melatonin Deficit: Beta-Blocker Therapy

A crucial, yet frequently overlooked, variable in geriatric cardiovascular care is the widespread use of beta-blockers. In the United States alone, tens of millions of elderly patients are chronically prescribed beta-blockers for hypertension, heart failure, and arrhythmias.

Medications such as propranolol and atenolol specifically antagonize β1-adrenergic receptors, the exact receptors on the pineal gland required for translating darkness cues into melatonin synthesis. Consequently, chronic beta-blocker therapy slashes endogenous nocturnal melatonin production by upwards of 50% to 86%. Clinical studies demonstrate that the specifically beta-blocking (S)-enantiomers of these drugs dramatically decrease the nocturnal production of melatonin, whereas non-beta-blocking enantiomers have no effect. Interestingly, carvedilol, which exhibits combined alpha- and beta-blocking properties, does not appear to suppress melatonin production to the same catastrophic degree, presenting a nuance in pharmacological selection.

This profound iatrogenic melatonin deficit is the primary biological driver of the pervasive sleep disturbances, insomnia, and vivid nightmares widely reported by patients on beta-blockers. The prolonged suppression of endogenous melatonin by these drugs also increases the risk for vascular white matter brain damage and exacerbates age-related neurodegeneration. Given the massive scale of beta-blocker prescriptions, the concurrent administration of exogenous melatonin is logically required to replace the biochemically suppressed hormone, restore sleep architecture, and prevent downstream neuropathology.

Beyond Chronobiology: Mitochondrial Targeted Protection

The most compelling argument for the prophylactic use of melatonin in all individuals over 60 lies in its receptor-independent actions at the subcellular level. Melatonin is a highly potent, endogenous free-radical scavenger that provides an exceptional defense against oxidative stress, particularly quenching the highly toxic hydroxyl radical, which is widely considered the most damaging free radical produced in the organism.

Mitochondrial Localization and Dynamics

Mitochondria are the primary source of reactive oxygen species (ROS) and are concurrently the primary victims of oxidative damage, leading to the gradual energy failure characteristic of biological aging and neurodegeneration. Strikingly, melatonin is not only synthesized exclusively within the mitochondrial matrix of pinealocytes and neuronal cells, but exogenously administered melatonin is actively and specifically targeted to the mitochondria via oligopeptide transporters (PEPT1 and PEPT2). This targeted accumulation allows melatonin to combat molecular terrorism precisely where it originates.

Within the mitochondria, melatonin mitigates injury by scavenging ROS, inhibiting the opening of the mitochondrial permeability transition pore (MPTP), and maintaining the mitochondrial membrane potential. Through these mechanisms, melatonin averts the catastrophic release of cytochrome c and halts the apoptotic cascade, protecting tissues from ischemic injury and neurotoxins.

SIRT1 and PGC-1α Mediated Mitochondrial Biogenesis

Melatonin’s protective role extends far beyond passive scavenging; it actively regulates genomic pathways to rejuvenate mitochondrial populations. Melatonin promotes mitochondrial biogenesis via the activation of the AMPK/SIRT1/PGC-1α signaling pathway. Sirtuin 1 (SIRT1) is a critical NAD-dependent histone deacetylase and well-established longevity protein that deacetylates and activates Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PGC-1α), the master regulator of mitochondrial biogenesis.

With advancing age, SIRT1 levels plummet, leading to attenuated mitochondrial biogenesis and severe energy deficits in highly metabolic tissues like the brain, heart, and liver. Exogenous melatonin restores SIRT1 expression and activity, rescuing tissues from toxic insults. In models of ischemia-reperfusion, cadmium toxicity, and rotenone exposure, melatonin successfully prevents excessive mitochondrial fission, restores functional mitochondrial mass, and preserves cellular viability. Furthermore, in total sleep-deprived subjects, melatonin preserves SIRT1 expression in the hippocampus, preventing the memory deficits and loss of neuronal plasticity associated with sleep loss.

Glymphatic Clearance and Alzheimer’s Disease Pathology

The aging brain relies on the glymphatic system—a macroscopic waste clearance network utilizing perivascular channels—to eliminate neurotoxic metabolic waste products, notably including amyloid-beta (Aβ), during deep sleep. Aging and the associated fragmentation of sleep severely impair this clearance mechanism, accelerating cerebral amyloidosis and the pathogenesis of Alzheimer’s disease.

Melatonin administration profoundly enhances glymphatic function. The mechanism is multifaceted: melatonin enhances deep sleep quality, heavily upregulates and maintains the polarization of aquaporin-4 (AQP4) channels on astrocyte end-feet (which facilitate bulk cerebrospinal fluid flow), and directly reduces neuroinflammation. Animal models demonstrate that melatonin supplementation reverses obesity-induced and aging-induced impairments in glymphatic Aβ clearance. In transgenic mouse models of Alzheimer’s disease (Tg2576), melatonin treatment successfully promotes the drainage of soluble monomeric Aβ into the cervical and axillary peripheral lymph nodes, confirming a robust enhancement of lymphatic clearance.

Furthermore, melatonin regulates the delicate balance of Aβ production and clearance, mitigating Aβ-induced neurotoxicity directly. In models of intracerebral hemorrhage (ICH), melatonin restores glymphatic transport, promotes rapid hematoma absorption, reduces blood-brain barrier (BBB) permeability, and rescues severe cognitive and behavioral deficits—effects that are partially reversed by the melatonin receptor antagonist luzindole. For a geriatric demographic at uniquely high risk for vascular dementia and Alzheimer’s disease, the daily enhancement of glymphatic flushing via scheduled melatonin administration is a biologically sound preventative strategy.

Prodromal Synucleinopathies and REM Sleep Behavior Disorder (RBD)

As a practicing sleep physician, one of the most clinically significant and ominous presentations in the geriatric clinic is isolated REM Sleep Behavior Disorder (iRBD). RBD is a parasomnia characterized by the loss of normal skeletal muscle atonia during REM sleep, leading to recurrent dream enactment behaviors that can be violent and injurious to the patient or their bed partner.

Crucially, modern neurology no longer views iRBD merely as an isolated sleep disruption; it is universally recognized as a prodromal α-synucleinopathy. An overwhelming majority of patients with iRBD will phenoconvert to Parkinson’s disease (PD), Lewy Body Dementia (LBD), or Multiple System Atrophy (MSA) within 10 to 20 years of onset. During this prolonged, decades-long prodromal phase, abnormalities in α-synuclein protein pathways, sustained neuroinflammation, and mitochondrial dysfunction slowly accumulate before motor symptoms ever manifest.

Melatonin as a Disease-Modifying Agent in RBD

While clonazepam has traditionally been utilized to suppress the violent symptoms of RBD, it carries the severe geriatric risks previously noted (falls, cognitive dulling) and does nothing to halt the underlying progressive neurodegeneration. Melatonin, typically administered at higher doses ranging from 2 mg to 12 mg, has emerged as a highly effective, well-tolerated therapy that actively restores REM sleep atonia and eliminates violent dream enactment.

More importantly, because iRBD patients represent an ideal population for neuroprotective interventions before widespread motor and cognitive collapse occurs, melatonin offers profound theoretical and observed disease-modifying potential. In a landmark longitudinal case report, a 72-year-old male with clinically and polysomnographically confirmed RBD and early signs of Parkinson’s disease—evidenced by reduced dopamine transporter density on a DaTSCAN—was treated with prolonged-release melatonin. Over successive years, not only did the clinical signs of RBD vanish and REM atonia normalize on follow-up polysomnography, but serial DaTSCAN imaging revealed a remarkable and unprecedented increase in striatal dopamine transporter density, ultimately showing a normalization of the scan with no signs of PD.

By quenching oxidative stress, supporting mitochondrial biogenesis, and clearing aberrant proteins, scheduled melatonin administration in seniors may serve to significantly delay, or potentially reverse, the pathophysiological cascade of α-synucleinopathies.

Cardiovascular Health and Autonomic Regulation

Aging is intimately associated with vascular stiffening, sympathetic overactivity, and the development of hypertension. A key prognostic indicator in hypertension is the patient’s “dipping” status—the physiological decline in blood pressure (BP) by 10% to 20% during sleep. Elderly patients frequently become “non-dippers,” a pathophysiological state that exponentially increases the risk of stroke, myocardial infarction, and end-organ damage.

Restoring Nocturnal Dipping

The nocturnal decline of BP is temporally coincident with the endogenous surge of melatonin, suggesting a direct mechanistic link. Clinical trials administering exogenous controlled-release (CR) melatonin (2 mg) to patients with nocturnal hypertension demonstrate that melatonin significantly reduces nocturnal systolic blood pressure by an average of 3.7 to 4.6 mmHg and diastolic BP by approximately 2.4 to 3.6 mmHg, without negatively altering daytime hemodynamics. Furthermore, melatonin therapy successfully restored a normal circadian dipping profile in over 30% of diabetic non-dippers.

It should be noted that while melatonin effectively reduces nocturnal BP, it does not alter blood pressure reactivity during acute physical or mental stress (such as cold pressor tests or isometric handgrip exercises), even in normotensive patients on high-sodium diets. This indicates that melatonin does not induce dangerous hypotensive instability, but rather restores the physiological day-night autonomic rhythm, which is highly cardioprotective.

Interestingly, population variances may exist. A preliminary randomized, crossover trial investigating high-dose, sustained-release melatonin in African-American patients with essential hypertension showed no significant decrease in nocturnal blood pressure compared to placebo. While further adequately powered trials are needed to clarify these inter-individual and demographic differences, the addition of melatonin to standard antihypertensive regimens generally represents a safe, synergistic approach to ameliorating nocturnal hypertension and reducing global cardiovascular risk in the elderly.

Immunosenescence and the NLRP3 Inflammasome

Aging is deeply characterized by “inflammaging”—a chronic, low-grade, sterile systemic inflammation that accelerates tissue degeneration across all organ systems. A central molecular mediator of inflammaging is the NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome. When activated by oxidative damage, metabolic stress, or mitochondrial dysfunction, the NLRP3 inflammasome triggers the maturation and rapid release of highly pro-inflammatory cytokines, specifically Interleukin-1β (IL-1β) and Interleukin-18 (IL-18).

Melatonin is a potent, targeted inhibitor of the NLRP3 inflammasome. By scavenging mitochondrial ROS (which acts as a primary trigger for inflammasome assembly) and modulating the NF-κB signaling pathway, melatonin prevents the physical formation of the NLRP3 complex. Clinically, the profound suppression of the NLRP3 inflammasome by melatonin has been shown to reduce age-dependent sarcopenia, preserve gastrocnemius muscle ultrastructure, and attenuate severe neuroinflammation in Parkinsonian models. Prophylactic use of melatonin therefore acts as an essential anti-inflammatory shield, combating systemic innate immune activation and preserving tissue function against immunosenescence.

Ophthalmic and Skeletal Degeneration

Age-Related Macular Degeneration (AMD)

AMD is the leading cause of severe visual loss in the elderly. The pathogenesis involves cumulative oxidative injury to the retinal pigment epithelium (RPE), local complement dysregulation, and severe mitochondrial dysfunction within the retina. The retina, remarkably, synthesizes its own localized pool of melatonin, which wanes with age parallel to pineal production.

Melatonin supplementation offers robust protection for the RPE. It safeguards RPE cells from oxidative stress (e.g., hydrogen peroxide toxicity), averts mitochondrial DNA damage, and inhibits VEGF to prevent neo-vascularization. Remarkably, melatonin stimulates local telomerase activity, overcoming the oxidative inhibition of telomere synthesis and preventing cellular senescence. In murine models of non-exudative AMD (induced by sodium iodate), melatonin effectively preserves retinal integrity, mitigates immune dysregulation via Regulatory T cell (Treg) recruitment (indicated by FOXP3 expression), and prevents the destruction of neurosensory and ganglionic neurons.

In a notable clinical study involving patients with both dry and wet AMD, daily administration of 3 mg of melatonin at bedtime stabilized visual acuity and resulted in remarkable funduscopic improvements, with the vast majority showing reduced pathologic macular changes, reduced bleeding, and reduced exudates. Recent epidemiological data rigorously corroborates this, demonstrating that melatonin use is associated with a significantly decreased risk of AMD development and progression.

Senile Osteoporosis

Bone remodeling is heavily influenced by circadian rhythms, and the age-related decline in melatonin is a critical factor driving postmenopausal and senile osteoporosis. Melatonin modulates bone homeostasis by acting directly on mesenchymal stem cells, heavily favoring osteoblast differentiation (osteogenesis) over adipocyte formation, while simultaneously suppressing osteoclast activity by reducing the RANKL/OPG ratio.

Furthermore, melatonin regulates autophagy within aged bone marrow-derived stem cells via the PIK3C-AKT-MTOR pathway, reversing degenerative osteogenesis and promoting extracellular matrix mineralization. In both postmenopausal and senile animal models, melatonin administration successfully restores bone mass, significantly increasing bone volume fraction (BV/TV) and trabecular thickness (Tb.Th), while decreasing trabecular separation (Tb.Sp). Given the catastrophic morbidity associated with osteoporotic hip fractures in the elderly, incorporating a bone-anabolic, universally safe chronobiotic like melatonin offers immense preventative value.

Refuting Criticisms of Universal Melatonin Adoption

Proposing the universal administration of any therapeutic agent across an entire demographic naturally invites skepticism. It is essential to rigorously address and refute the prevailing criticisms surrounding melatonin use in the elderly, as many of these objections stem from a fundamental misunderstanding of the molecule’s chronobiotic and pleiotropic properties.

Criticism 1: “Melatonin has weak or clinically insignificant efficacy for primary insomnia compared to prescription hypnotics.” This criticism relies on a false equivalency. Melatonin is a chronobiotic, not a central nervous system depressant. While GABAergic drugs (like benzodiazepines and Z-drugs) forcefully induce an artificial state of unconsciousness accompanied by altered sleep architecture, melatonin gently cues the brain’s suprachiasmatic nucleus to initiate physiological sleep. The benefits of melatonin compound over time. By restoring the circadian amplitude, it naturally shortens sleep latency and extends sleep time without altering the physiological proportion of REM and non-REM sleep. The goal of geriatric sleep medicine must be the restoration of natural sleep architecture, not chemically enforced sedation, making melatonin the vastly superior choice for long-term health.

Criticism 2: “Exogenous melatonin causes vivid dreams, nightmares, or morning ‘hangover’ effects.” These adverse effects are almost exclusively the result of improper dosing or incorrect circadian timing. Melatonin must be administered at a fixed and regular bedtime (e.g., 30 to 60 minutes prior to intended sleep) to correctly entrain the circadian rhythm. Taking melatonin irregularly, in the middle of the night, or in massive supra-physiological boluses (>10 mg) for simple insomnia can lead to phase-shifting errors that manifest as morning grogginess or intense REM rebound. When used correctly at physiological or low pharmacological doses (0.3 mg to 3 mg, particularly in prolonged-release forms), the incidence of daytime sedation, weakness, or grogginess is comparable to placebo.

Criticism 3: “Regular use will suppress the body’s natural production of melatonin and create dependency.” Unlike the hypothalamic-pituitary-adrenal (HPA) axis or the thyroid axis, the pineal gland does not operate on a negative feedback loop mediated by circulating melatonin levels. Decades of research have shown that exogenous melatonin administration does not suppress endogenous pineal synthesis, nor does it cause glandular atrophy. Furthermore, cessation of therapy does not result in withdrawal symptoms or rebound insomnia, confirming a lack of physiological dependency. Moreover, since the geriatric pineal gland is already severely calcified and functionally compromised, the fear of suppressing an already defunct endogenous system is biologically unfounded.

Criticism 4: “Melatonin lowers blood pressure, which could cause dangerous hypotension or falls in the elderly.” While melatonin does influence hemodynamics, its effects are modulatory rather than purely hypotensive. Melatonin specifically targets the pathology of nocturnal non-dipping, reducing nighttime systolic pressure by a modest 3.7 to 4.6 mmHg. It does not induce clinically significant daytime hypotension, orthostatic hypotension, or alter blood pressure reactivity during acute physical stress. Instead, it restores the physiological day-night autonomic rhythm. While caution is always advised regarding fall risks in the elderly, melatonin’s lack of muscle relaxation or ataxia makes it exponentially safer than benzodiazepines.

Criticism 5: “Adding melatonin exacerbates the problem of polypharmacy in the elderly.” The integration of melatonin is specifically designed to reduce harmful polypharmacy. By effectively managing sleep disturbances, mitigating beta-blocker-induced insomnia, and providing baseline neuroprotection, melatonin allows for the active deprescribing of highly toxic medications. These include benzodiazepines, atypical antipsychotics used off-label for sleep, and anticholinergic sleep aids that exacerbate dementia. Melatonin acts as an endogenous replacement therapy that synergizes with, rather than complicates, the geriatric physiological state.

Conclusion

The age-related calcification of the pineal gland and the subsequent collapse of melatonin production is not a benign consequence of chronological aging; it is a fundamental pathological deficit that accelerates systemic degeneration. Based on exhaustive molecular evidence and decades of clinical observation, melatonin represents far more than an over-the-counter sleep aid. It is a highly potent, mitochondria-targeted antioxidant, a critical driver of SIRT1/PGC-1α mediated mitochondrial biogenesis, an enhancer of glymphatic amyloid clearance, a suppressor of the NLRP3 inflammasome, and a critical regulator of osteoblastic and retinal health.

For the geriatric population, the benefits of scheduled melatonin supplementation are unparalleled. It restores physiological sleep architecture without the catastrophic fall and dementia risks inextricably linked to benzodiazepines. It specifically reverses the profound iatrogenic sleep disturbances caused by ubiquitous beta-blocker therapies. Furthermore, its proven efficacy in halting the violent symptoms of REM Sleep Behavior Disorder (RBD)—a prodromal phase of Parkinson’s and Lewy Body diseases—highlights its profound potential as a neuroprotective, disease-modifying agent capable of altering the trajectory of α-synucleinopathies.

Therefore, it is the strong clinical recommendation of this report that the daily administration of melatonin, taken consistently at a fixed and regular bedtime, be adopted as a universal prophylactic and therapeutic standard of care for all adults older than 60. By safely replacing this lost endogenous defender, the medical community can effectively improve the health span, preserve cognitive longevity, and elevate the overall quality of life for the aging population.